Loading people...
Imran Eba is the Chief Financial Officer at Alpheus Medical, an oncology therapy technology developer based in Cambridge, Massachusetts. Prior to assuming this role in May 2025, he served as a founding Partner at Action Potential Venture Capital, a specialized corporate venture fund established in 2013 with an initial $50 million commitment from GlaxoSmithKline. At GlaxoSmithKline, Eba spent over eight years as a Vice President in the Worldwide Business Development group, where he directed the firm's investment management practice for direct biotech allocations and limited partner commitments. As an investor, he co-led a Series B financing round for Alpheus Medical in 2020 and held board director positions at several medical device startups, including Axon Therapies, Neuspera Medical, and SetPoint Medical. His career focuses on advancing bioelectronic medicines and peripheral neuromodulation therapies designed to treat chronic diseases.
Imran Eba is a Partner at Action Potential Venture Capital, a firm specializing in investments within the life sciences and technology sectors. He is known for his strategic role in identifying and supporting innovative companies, particularly those focused on biotechnology, neuroscience, and advanced healthcare solutions.
Imran Eba primarily invests in early-stage and growth-stage companies within the biotechnology, neuroscience, and broader health technology sectors. His focus includes novel therapeutics, advanced diagnostics, neuro-tech innovations, and digital health platforms that aim to address significant medical needs and improve human health.
Imran Eba works as a Partner at Action Potential Venture Capital. This venture capital firm is dedicated to investing in groundbreaking companies that are at the forefront of scientific discovery and technological innovation, particularly within the life sciences and healthcare industries.
Imran Eba is a distinguished Partner at Action Potential Venture Capital, a firm renowned for its strategic investments in the frontier of life sciences and technology. In his capacity, Eba is instrumental in shaping the firm's investment strategy, leading due diligence processes, and actively supporting portfolio companies from inception through growth. His work at Action Potential Venture Capital involves a deep commitment to identifying visionary founders and disruptive technologies that promise to redefine healthcare and human potential.
Eba's investment focus at Action Potential Venture Capital is primarily directed towards early-stage and growth-stage companies operating within the biotechnology, neuroscience, and broader health technology sectors. This includes ventures exploring novel therapeutics, advanced diagnostics, neuro-tech innovations, and digital health platforms that leverage cutting-edge science to address unmet medical needs. He is particularly interested in technologies that demonstrate strong scientific validation and possess the potential for significant market impact, driving both commercial success and societal benefit. His expertise allows him to discern promising opportunities in complex scientific domains, guiding investments towards solutions that can truly make a difference.
Prior to his role at Action Potential Venture Capital, Imran Eba built a robust career foundation characterized by a blend of scientific acumen and strategic business development. While specific details of his early career are not publicly detailed, his trajectory suggests a background that equipped him with a profound understanding of both the scientific landscape and the intricacies of venture capital. This diverse experience has provided him with a unique perspective, enabling him to effectively bridge the gap between scientific discovery and market realization. He is known for his analytical rigor, strategic foresight, and ability to foster strong relationships with entrepreneurs and co-investors.
As a Partner, Imran Eba is deeply involved in the lifecycle of Action Potential Venture Capital's portfolio companies. While specific notable investments are not publicly disclosed, his contributions are vital in nurturing these ventures, providing strategic guidance, and helping them navigate the challenges of scaling innovative technologies. He works closely with founders to refine business models, accelerate product development, and prepare for subsequent funding rounds. Eba's dedication to fostering innovation and supporting transformative companies underscores his commitment to advancing the future of health and technology through strategic venture capital. His leadership helps Action Potential Venture Capital remain at the forefront of investing in the next generation of life science breakthroughs.
